Testing and Diagnostics Library
Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 97–120 of 314
IPA Nanosensor Decodes Gut Microbial Metabolism in Minutes
Researchers in Singapore have developed a fluorescent nanosensor that detects indole-3-propionic acid (IPA), a microbial metabolite, within minutes using optical readout instead of mass spectrometry. This advancement accelerates access to gut biomarker testing and supports the clinical shift toward preventive medicine and personalized metabolic assessment.
Perplexity enters the consumer health AI arena
Perplexity has launched an AI-powered health platform that aggregates fragmented health data from medical records, wearables, and provider systems into a unified dashboard, enabling personalized health insights grounded in individual biomarkers and trends. This addresses a critical infrastructure gap in longevity practice: the ability to contextualize health signals across time and across systems, moving beyond isolated data points toward pattern recognition that supports earlier intervention.
PREMAZ expands early brain screening through Health is One
PREMAZ, a digital cognitive assessment tool, has partnered with Health is One to integrate early brain screening into everyday wellness services rather than clinical settings. The platform measures memory precision—the sharpness and reliability of recall—to detect subtle cognitive changes before decline becomes clinically apparent, shifting brain health assessment from reactive to preventive.
Reducing cardiovascular risk: a playbook for lipid-lowering pharmacotherapy
A systematic approach to lipid-lowering pharmacotherapy uses risk stratification and a six-step protocol to guide drug selection and escalation, optimizing cardiovascular protection across heterogeneous patient populations. This framework addresses the gap between guideline recommendations and individualized clinical decision-making in managing atherosclerotic cardiovascular disease risk.
AI Halves Drug Discovery Timeline for Neuroimmune Disease
A $2.5 billion partnership between Insilico Medicine and SK Biopharmaceuticals targets neuroimmune disorders using AI-accelerated drug discovery, reducing early-stage development timelines from 2-4 years to 12-18 months. This collaboration signals industry-wide confidence that AI can meaningfully improve outcomes for diseases where traditional approaches have repeatedly failed.
AliveCor expands AI 12-lead cardiac diagnostics to Vietnam
AliveCor's Kardia 12L, an AI-powered portable 12-lead electrocardiogram system, has secured regulatory registration in Vietnam to enable hospital-grade cardiac diagnostics at point of care. The device reduces acquisition time by approximately 30% and simplifies electrode setup, allowing earlier detection of arrhythmias, myocardial infarction, and cardiac ischemia in community and outpatient settings.
Mirroring tissue senescence in human biofluids
Researchers have developed a non-invasive urine-based biomarker panel to monitor cellular senescence and track the efficacy of senolytic therapies. This approach enables real-time assessment of senescent cell burden without tissue biopsy, creating a practical pathway for personalized intervention monitoring in aging-related disease.
AI model detects Alzheimer's pathology before symptom onset
A convolutional neural network model (AlzheiNN) achieves 99.7% accuracy in classifying Alzheimer's disease from neuroimaging data, outperforming traditional diagnostic methods. Early and accurate detection of neurodegenerative disease significantly impacts the window for intervention and the trajectory of cognitive decline.
Life Time rolls out SpiroFit metabolic testing to country clubs
Life Time is deploying SpiroFit, a cordless wearable metabolic testing system, across 190 clubs to measure VO2 max and fuel utilization during exercise. The technology generates personalized heart-rate training zones with lab-grade accuracy, enabling members to optimize training intensity and metabolic efficiency.
Region-specific transcriptional signatures of brain aging in the absence of neuropathology at the single-cell level
Single-cell transcriptional analysis reveals region-specific aging signatures in the brain that occur independently of classical neuropathology, suggesting aging involves coordinated transcriptional changes across distinct neural populations. This finding establishes a molecular basis for understanding how brain regions age differently and may identify intervention points before pathological hallmarks emerge.
AI drug discovery benchmark cuts preclinical nomination to 12-18 months
Insilico Medicine established a standardized benchmarking service for evaluating AI drug discovery platforms against validated datasets and expert baselines. This infrastructure addresses a critical gap in translating computational drug discovery into clinical candidates, offering organizations a quantified method to assess AI model performance in hit identification and preclinical nomination.
Multi-tissue transcriptomic aging atlas reveals predictive aging biomarkers in the killifish
Researchers created a multi-tissue transcriptomic atlas across thirteen tissues in African turquoise killifish at six life stages, identifying molecular patterns of aging that vary by tissue type and sex. This resource establishes predictive biomarkers for aging dynamics and demonstrates how systemic and local factors drive age-related changes across the organism.
Insilico Medicine and Liquid AI partner to build science‑oriented AI models for drug discovery
Insilico Medicine and Liquid AI are developing specialized AI foundation models to accelerate drug discovery by improving molecular prediction, biological activity forecasting, and compound design. This partnership demonstrates how computational efficiency in scientific AI can reduce timelines for therapeutic development while making tools accessible across the research community.
January AI enters Medicare App Library, reaches 69m+ patients
The CMS Medicare App Library now includes January AI, a data integration platform that translates fragmented health records into actionable insights for 69 million Medicare beneficiaries. This represents a structural shift toward patient-controlled healthcare where individuals access their own data and receive personalized guidance on immediate decisions—particularly relevant for older adults managing chronic disease.
Study finds daily multivitamin can ease signs of biological aging
A two-year study of 958 adults aged 70+ found that daily multivitamin use slowed biological aging markers measured through epigenetic clocks, with the effect most pronounced in participants showing accelerated aging. While the slowdown was modest—measured in months rather than years—the consistent effect across multiple aging biomarkers suggests multivitamins may influence cellular-level processes relevant to healthspan rather than lifespan extension.
Cognision launches cognision360 platform for CNS trial biomarkers
Cognision360 consolidates neurobiomarker data collection and analysis for CNS clinical trials through automated workflows and standardized integration of EEG, sleep, eye tracking, wearables, and cognitive assessments. The platform addresses fragmentation in multi-site studies and accelerates regulatory pathways by improving data integrity and reducing manual processing errors.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health, combining epigenetic testing platforms, laboratory infrastructure, and personalized intervention products. The merger positions epigenetic age assessment as a diagnostic tool paired with targeted supplementation and lifestyle recommendations for consumers pursuing longevity optimization.
Insilico Medicine, Lilly partner on AI-driven drug discovery deal
Insilico Medicine and Eli Lilly have established a drug discovery partnership leveraging AI to accelerate identification and development of oral therapeutics across multiple disease areas. This collaboration represents a shift in pharmaceutical R&D methodology toward computational drug discovery, with potential implications for reducing development timelines and costs in longevity-related therapeutic areas.
AI-driven bioengineering platforms revolutionize protein design
AI-driven bioengineering platforms are accelerating protein design and drug discovery by computational screening of millions of proteins and billions of compounds annually, reducing traditional wet-lab timelines. This technological shift reshapes how therapeutic candidates are identified and optimized, with governments globally investing multibillion-dollar programs to scale these capabilities.
Tiny gene reveals splicing’s role in disease
Researchers mapped functional consequences of hundreds of mutations in RNU4-2, a 145-base non-coding RNA gene within the spliceosome, linking splicing dysfunction to neurodevelopmental disorders affecting approximately 100,000 individuals globally. This work establishes a systematic framework for interpreting non-coding variants and refines genomic diagnosis beyond association to functional mechanism.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health to integrate epigenetic testing with clinical infrastructure and consumer interventions, creating a closed-loop system that aims to move biological age measurement from research curiosity into actionable preventive healthcare. The consolidation represents an attempt to resolve the gap between epigenetic data capture and demonstrable clinical outcomes.
Amydis lands NIA funding to detect ALS in the eye
Amydis has secured $2.5 million in Phase 2 NIH funding to develop a non-invasive eye-imaging technology that detects TDP-43, a protein biomarker present in over 97% of ALS cases. Early detection through a simple retinal scan could compress the current 9-12 month diagnostic timeline and enable earlier therapeutic intervention in a disease where time is critical.
AI-Powered Brain Models Enable Precision Drug Matching
Verge Labs has rebranded as an AI-focused company building computational models from 12,000+ human brain samples to predict drug efficacy and identify optimal patient populations before clinical trials. This approach addresses a fundamental failure mode in drug development: testing the wrong target in the wrong patients.
AI platform maps brain disease mechanisms via multimodal clinical data
Verge Labs has established a frontier AI platform trained on VergeDB, a proprietary multimodal dataset of over 12,000 brain transcriptomes and matched molecular, clinical, and imaging data from living patients. The platform's disease targets have validated at 83 percent accuracy against experimental confirmation, with its first AI-discovered CNS asset advancing through Phase 1b trials, positioning machine learning as a substantive tool for accelerating central nervous system drug development.